Towards arresting type 1 diabetes: Breaking results of the MELD-ATG & Ver-A-T1D trials

Show notes

Watch the full video on YouTube to explore the latest findings from two major clinical trials investigating disease-modifying therapies for type 1 diabetes.

In this episode, Prof. Chantal Mathieu (KU Leuven, endocrinologist and leading researcher in type 1 diabetes) and Prof. Francesco Dotta (University of Siena, expert in type 1 diabetes pathophysiology and clinical trials) discuss the MELD-ATG and VERA-T1D trials conducted through the European INNODIA consortium.

Topics include:

  • The goals of the INNODIA consortium and its role in advancing type 1 diabetes research
  • The VERA-T1D trial, testing verapamil as a potential beta-cell protective therapy
  • Why the trial narrowly missed its primary endpoint but still provides important clinical insights
  • The MELD-ATG adaptive trial, identifying a low-dose immunotherapy that can delay beta-cell decline
  • How innovative trial designs allow researchers to optimise dosing strategies
  • The importance of biomarkers and precision medicine approaches in type 1 diabetes

Explore the latest EASD Annual Meeting presentations and learn more about our expert speakers:

  1. Prof. Chantal Mathieu
  2. Prof. Francesco Dotta

For more expert conversations, explore our podcast archive.

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.